SecBot SecBot
SECBOTREPLAY Home › Report › ARVN

ARVN · Arvinas announced a pipeline reprioritization, planning to complete the…

ARVINAS, INC. · 8-K filed Jun 2, 2026 at 16:39 ET

At the news

BEARISHIMPACT 6/10

8-K filed Jun 2, 2026 at 16:39 ET

Arvinas announced a pipeline reprioritization, planning to complete the Phase 1 monotherapy dose escalation trial for ARV-806 (KRAS G12D) and then seek an out-licensing partner for further development. The company also furnished an investor presentation for the Jefferies Global Healthcare Conference. Cash runway extends into H2 2028.

  • Arvinas is deprioritizing ARV-806, its KRAS G12D program, after completing Phase 1 dose escalation enrollment in Q2 2026.
  • The company plans to out-license any further clinical trials (dose expansion or combination) for ARV-806.
  • Cash, cash equivalents, and marketable securities as of March 31, 2026 are expected to fund operations into H2 2028.
  • An investor presentation was furnished for the Jefferies Global Healthcare Conference on June 3, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access